1. Gestational female patients, 2. Patients with other malignant diseases such as malignant tumours, chronic liver or kidney diseases, and reaching the end stage, 3. Patients with known psychiatric disorders, 4. Patients withdrawing from other clinical trial within 4 weeks.

1. Gestational female patients, 2. Patients with other malignant diseases such as malignant tumours, chronic liver or kidney diseases, and reaching the end stage, 3. Patients with known psychiatric disorders, 4. Patients withdrawing from other clinical trial within 4 weeks.